Strata Skin Sciences (FRA:E2O) Total Current Liabilities: €22.84 Mil (As of Dec. 2025)


FRA:E2O Strata Skin Sciences Inc FRA:E2O
38 GF Score
Price €3.76
GF Value €19,176.00
! 4 Warning Signs
View Full Analysis

What is Strata Skin Sciences Total Current Liabilities?

Strata Skin Sciences FRA:E2O 38 Total Current Liabilities is €22.84 Mil as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €19,176.00. The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Strata Skin Sciences's total current liabilities for the quarter that ended in Dec. 2025 was €22.84

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Strata Skin Sciences Total Current Liabilities Related Terms

Strata Skin Sciences Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences Total Current Liabilities Chart

Strata Skin Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 12.67 11.16 12.79 22.84

Strata Skin Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.79 14.00 12.14 12.81 22.84
FRA:E2O
38GF Score
Strata Skin Sciences Inc FRA:E2O
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strata Skin Sciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Strata Skin Sciences's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.978+13.305
+Other Current Liabilities+Current Deferred Liabilities
=1.634+1.92
=22.84

Strata Skin Sciences's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.978+13.305
+Other Current Liabilities+Current Deferred Liabilities
=1.634+1.92
=22.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €22.84 Mil mean?
Strata Skin Sciences (FRA:E2O) has a Total Current Liabilities of €22.84 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Strata Skin Sciences and its competitors.
Is Strata Skin Sciences' Total Current Liabilities too high?
Strata Skin Sciences' current Total Current Liabilities is €22.84 Mil. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Total Current Liabilities compare to ODYY and NUMD?
Strata Skin Sciences' Total Current Liabilities of €22.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Strata Skin Sciences and its competitors. Strata Skin Sciences's current Total Current Liabilities is €22.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Total Current Liabilities of €22.84 Mil. The stock's GF Value™ is €19,176.00, compared to a current price of €3.76 — trading 100% below its estimated fair value. The current Total Current Liabilities is €22.84 Mil. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Total Current Liabilities is €22.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 100% below its estimated GF Value™ of €19,176.00.

Key valuation signals for FRA:E2O:

  • Total Current Liabilities: €22.84 Mil
  • GF Value™: €19,176.00 vs. price of €3.76 (100% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Skin Sciences Business Description

Other Exchanges SSKN:USA
Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score

Get the complete analysis for FRA:E2O

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76
Price
€19,176.00
GF Value